- Second-line lenvatinib is well-tolerated and shows modest antitumor response in patients with recurrent endometrial cancer.
Why this matters
- Recurrent endometrial cancer is difficult to treat, and previous studies in this setting did not show improved survival.
- Phase 2 study: 133 patients with unresectable endometrial cancer who relapsed after 1 previous platinum-based chemotherapy received lenvatinib.
- Funding: Eisai Inc; MSD.
- Objective response rate (ORR) was 14.3% (95% CI, 8.8%-21.4%).
- The median duration of response was 7.2 months.
- The median PFS was 5.6 months, and the median OS was 10.6 (95% CI, 8.9-14.9) months.
- The most common grade ≥3 treatment-related adverse events were hypertension (33%), fatigue (12%), asthenia (10%), abdominal pain (6%), proteinuria (8%), and dehydration (6%).
- Patients with lower baseline levels of angiopoietin-2 levels showed:
- Longer PFS (highest vs lowest quartile): 225.0 vs 86.5 days.
- Longer OS (highest vs lowest quartile): 541.0 vs 173.0 days.
- Higher ORR: 26.9% vs 5.7%.
- Treatment-related discontinuation rate was 18%.
- Single-group, open-label design.